ClinicalTrials.gg
CompletedNCT04016753Updated May 31, 2022

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

A Phase 1 interventional study of BMS-986256 and Loestrin in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to female participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Feb 2020, 6 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
21 Years to 40 Years
Sex
Female
01

Study summary

A comparative study of BMS-986256 with a combined oral contraceptive in healthy female participants to determine the effectiveness when taken together

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be a non- smoking genetically female, who has normal renal function, willing to use Loestrin, and of with intact ovarian function.
  • Participants must be healthy, defined as having no active or ongoing medical condition Weighing less than or equal to 50 kg and a between 18.0 and 32.0kg inclusive at screening.
  • Participant must have a negative QuantiFeron- TB Gold test at screening and have a normal pap smear result within 3 years.

Exclusion criteria

Exclusion Criteria:

  • Participants who are involuntarily incarcerated, have a significant Chronic medical illness or a history of relevant drug allergy to immunologic or related compounds.
  • Any serious bacterial, fungal, or viral infection within 3 months or a history of recurrent or chronic infection or Risk for TB.
  • A history of any medical condition specifically related to the use of hormonal as well as an average intake of more than 21 units of alcohol per week.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Monotherapy

    Drug: BMS-986256 · Drug: Loestrin

Interventions

  • 30 mg(6ml)

  • DrugLoestrin

    1.5 mg Norethindrone and 30ug ethinyl estradiol

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma Concentration (Cmax) of Norethindrone (NET)

    Time frame: Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)

  2. Area under the plasma concentration-time curve over the dosing interval AUC(TAU) of NET

    Time frame: Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)

  3. Maximum observed plasma Concentration (Cmax) of Ethinyl Estradiol (EE)

    Time frame: Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)

  4. Area under the plasma concentration-time curve over the dosing interval AUC(TAU)of (EE)

    Time frame: Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 28 weeks

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 28 weeks

  3. Serology clinical lab assessment of blood

    Time frame: up to 28 weeks

  4. Hematology clinical lab assessments of blood

    Time frame: up to 28 weeks

  5. Urinalysis clinical lab assessment

    Time frame: up to 28 weeks

  6. Vital signs of blood pressure

    Time frame: up to 28 weeks

  7. Vital signs of body temperature

    Time frame: up to 28 weeks

  8. Vital signs of respiratory rate

    Time frame: up to 28 weeks

  9. Number of Participants with abnormal physical examination findings

    Time frame: up to 28 weeks

07

Study locations

1 site
  • Altasciences Los Angeles (Formerly WCCT Global)
    Cypress, California 90630, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Feb 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Jul 11, 2019
StartActual
Aug 5, 2019
Primary completionActual
Feb 21, 2020
CompletionActual
Feb 21, 2020
Last update
May 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04016753
Responsible party
Sponsor
First posted
Jul 11, 2019
Start date
Aug 5, 2019
Primary completion
Feb 21, 2020
Completion
Feb 21, 2020
Last update
May 31, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion